Enoxaparin sodium 20mg PFS
Product Overview
| Generic Name | Enoxaparin sodium 20mg PFS |
| Brand Name(s) | Lovenox, Clexane, Xaparin |
| Category | Cardiovascular |
| Form | PFS, Subcutaneous or Intravenous |
| Strength | 20 mg/0.4mL |
| Therapeutic Class | Antithrombotic agent: |
| ATC Code | B01AB05 |
Manufacturing & Regulatory
| Manufacturer | Sanofi, Other Biosimilar mfgs |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available per batch upon request |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Manufacturer provides standard SDS (biologic/aqueous injectable) |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
Indications & Usage: Enoxaparin sodium is indicated for prophylaxis and treatment of venous thromboembolism (DVT/PE), unstable angina, non‑ST elevation myocardial infarction, perioperative prophylaxis (hip/knee/abdominal surgery), prevention of clotting during hemodialysis. Acts by potentiating antithrombin III to inhibit factor Xa (and IIa); predictable pharmacokinetics; reversal partial with protamine sulfate